Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Gloucester's Istodax Gains FDA Approval Ahead Of New Regulatory Requirements

This article was originally published in The Pink Sheet Daily

Executive Summary

With FDA's approval a week ahead of the PDUFA date, Gloucester Pharmaceuticals will bring its first product to market, the second HDAC inhibitor approved in cancer.

You may also be interested in...

EMA Approves Three Oncology Drugs, Rejects One

Cancer drugs had a triumphant day at the European Medicines Agency on July 20, led by Pfizer’s Xalkori, with only one (Celgene’s Istodax) failing to make the grade.

Former Yaupon Therapeutics Raises $15 Million In Debt To Prepare To Commercialize Its First Product

Now called Ceptaris, the company is awaiting FDA approval of mechlorethamine gel, a topical formulation of a cytotoxin, for early-stage CTCL.

Buoyed by Positive Trial Data, Private Yaupon Prepares To File Topical Chemo For Early CTCL

FDA orphan R&D grant and academic ties start to pay off for biotech's lead drug, a topical gel of a generic chemotherapy aimed at 20,000 patients with early-stage skin cancer.

Related Content





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts